Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Effects of dengue immunity on Zika virus infection.

Whitehead SS, Pierson TC.

Nature. 2019 Mar;567(7749):467-468. doi: 10.1038/d41586-019-00868-6. No abstract available.

PMID:
30911157
2.

Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.

Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS.

J Infect Dis. 2019 Jun 19;220(2):219-227. doi: 10.1093/infdis/jiz109.

3.

Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.

Nivarthi UK, Tu HA, Delacruz MJ, Swanstrom J, Patel B, Durbin AP, Whitehead SS, Pierce KK, Kirkpatrick BD, Baric RS, Nguyen N, Emerling DE, de Silva AM, Diehl SA.

EBioMedicine. 2019 Mar;41:465-478. doi: 10.1016/j.ebiom.2019.02.060. Epub 2019 Mar 8.

4.

Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3.

Campbell RA, Schwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Kirkpatrick BD, Pierce KK, Whitehead SS, Diehl SA, Bray PF, Zimmerman GA, Kosaka Y, Bozza PT, Bozza FA, Weyrich AS, Rondina MT.

Blood. 2019 May 9;133(19):2013-2026. doi: 10.1182/blood-2018-09-873984. Epub 2019 Feb 5.

PMID:
30723081
5.

Routes of Zika virus dissemination in the testis and epididymis of immunodeficient mice.

Tsetsarkin KA, Maximova OA, Liu G, Kenney H, Teterina N, Bloom ME, Grabowski JM, Mlera L, Nagata BM, Moore I, Martens C, Amaro-Carambot E, Lamirande EW, Whitehead SS, Pletnev AG.

Nat Commun. 2018 Dec 17;9(1):5350. doi: 10.1038/s41467-018-07782-x.

6.

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.

Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS.

Cell Rep. 2018 Oct 30;25(5):1214-1224. doi: 10.1016/j.celrep.2018.10.006.

7.

Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus.

Katzelnick LC, Coello Escoto A, McElvany BD, Chávez C, Salje H, Luo W, Rodriguez-Barraquer I, Jarman R, Durbin AP, Diehl SA, Smith DJ, Whitehead SS, Cummings DAT.

PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862. doi: 10.1371/journal.pntd.0006862. eCollection 2018 Oct.

8.

Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.

Popper SJ, Strouts FR, Lindow JC, Cheng HK, Montoya M, Balmaseda A, Durbin AP, Whitehead SS, Harris E, Kirkpatrick BD, Relman DA.

J Infect Dis. 2018 Nov 5;218(12):1911-1921. doi: 10.1093/infdis/jiy434.

PMID:
30010906
9.

Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon.

Bustos-Arriaga J, Gromowski GD, Tsetsarkin KA, Firestone CY, Castro-Jiménez T, Pletnev AG, Cedillo-Barrón L, Whitehead SS.

Vaccine. 2018 Jun 7;36(24):3460-3467. doi: 10.1016/j.vaccine.2018.04.087. Epub 2018 May 8.

PMID:
29752023
10.

Lethal Zika Virus Disease Models in Young and Older Interferon α/β Receptor Knock Out Mice.

Marzi A, Emanuel J, Callison J, McNally KL, Arndt N, Chadinha S, Martellaro C, Rosenke R, Scott DP, Safronetz D, Whitehead SS, Best SM, Feldmann H.

Front Cell Infect Microbiol. 2018 Apr 11;8:117. doi: 10.3389/fcimb.2018.00117. eCollection 2018.

11.

Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques.

Magnani DM, Rogers TF, Maness NJ, Grubaugh ND, Beutler N, Bailey VK, Gonzalez-Nieto L, Gutman MJ, Pedreño-Lopez N, Kwal JM, Ricciardi MJ, Myers TA, Julander JG, Bohm RP, Gilbert MH, Schiro F, Aye PP, Blair RV, Martins MA, Falkenstein KP, Kaur A, Curry CL, Kallas EG, Desrosiers RC, Goldschmidt-Clermont PJ, Whitehead SS, Andersen KG, Bonaldo MC, Lackner AA, Panganiban AT, Burton DR, Watkins DI.

Nat Commun. 2018 Apr 24;9(1):1624. doi: 10.1038/s41467-018-04056-4.

12.

Zika Vaccines: Role for Controlled Human Infection.

Durbin AP, Whitehead SS.

J Infect Dis. 2017 Dec 16;216(suppl_10):S971-S975. doi: 10.1093/infdis/jix491. Review.

13.

Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL.

Ricciardi MJ, Magnani DM, Grifoni A, Kwon YC, Gutman MJ, Grubaugh ND, Gangavarapu K, Sharkey M, Silveira CGT, Bailey VK, Pedreño-Lopez N, Gonzalez-Nieto L, Maxwell HS, Domingues A, Martins MA, Pham J, Weiskopf D, Altman J, Kallas EG, Andersen KG, Stevenson M, Lichtenberger P, Choe H, Whitehead SS, Sette A, Watkins DI.

PLoS Negl Trop Dis. 2017 Dec 21;11(12):e0006000. doi: 10.1371/journal.pntd.0006000. eCollection 2017 Dec.

14.

Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques.

Magnani DM, Rogers TF, Beutler N, Ricciardi MJ, Bailey VK, Gonzalez-Nieto L, Briney B, Sok D, Le K, Strubel A, Gutman MJ, Pedreño-Lopez N, Grubaugh ND, Silveira CGT, Maxwell HS, Domingues A, Martins MA, Lee DE, Okwuazi EE, Jean S, Strobert EA, Chahroudi A, Silvestri G, Vanderford TH, Kallas EG, Desrosiers RC, Bonaldo MC, Whitehead SS, Burton DR, Watkins DI.

Sci Transl Med. 2017 Oct 4;9(410). pii: eaan8184. doi: 10.1126/scitranslmed.aan8184.

15.

Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.

Magnani DM, Silveira CGT, Ricciardi MJ, Gonzalez-Nieto L, Pedreño-Lopez N, Bailey VK, Gutman MJ, Maxwell HS, Domingues A, Costa PR, Ferrari L, Goulart R, Martins MA, Martinez-Navio JM, Fuchs SP, Kalil J, Timenetsky MDC, Wrammert J, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI.

J Virol. 2017 Oct 27;91(22). pii: e00867-17. doi: 10.1128/JVI.00867-17. Print 2017 Nov 15.

16.

Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.

Magnani DM, Ricciardi MJ, Bailey VK, Gutman MJ, Pedreño-Lopez N, Silveira CGT, Maxwell HS, Domingues A, Gonzalez-Nieto L, Su Q, Newman RM, Pack M, Martins MA, Martinez-Navio JM, Fuchs SP, Rakasz EG, Allen TM, Whitehead SS, Burton DR, Gao G, Desrosiers RC, Kallas EG, Watkins DI.

Mol Ther. 2017 Oct 4;25(10):2323-2331. doi: 10.1016/j.ymthe.2017.06.020. Epub 2017 Jul 24.

17.

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Whitehead SS, Subbarao K.

Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6). pii: a028811. doi: 10.1101/cshperspect.a028811. Review.

PMID:
28716894
18.

A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus.

Magnani DM, Silveira CGT, Rosen BC, Ricciardi MJ, Pedreño-Lopez N, Gutman MJ, Bailey VK, Maxwell HS, Domingues A, Gonzalez-Nieto L, Avelino-Silva VI, Trindade M, Nogueira J, Oliveira CS, Maestri A, Felix AC, Levi JE, Nogueira ML, Martins MA, Martinez-Navio JM, Fuchs SP, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI.

PLoS Negl Trop Dis. 2017 Jun 12;11(6):e0005655. doi: 10.1371/journal.pntd.0005655. eCollection 2017 Jun.

19.

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.

Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD.

PLoS Negl Trop Dis. 2017 May 8;11(5):e0005584. doi: 10.1371/journal.pntd.0005584. eCollection 2017 May.

20.

Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

Grifoni A, Angelo M, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Botten J, Boyson J, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D.

J Virol. 2017 Mar 29;91(8). pii: e02133-16. doi: 10.1128/JVI.02133-16. Print 2017 Apr 15.

21.

A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.

Pierce KK, Whitehead SS, Kirkpatrick BD, Grier PL, Jarvis A, Kenney H, Carmolli MP, Reynolds C, Tibery CM, Lovchik J, Janiak A, Luke CJ, Durbin AP, Pletnev AG.

J Infect Dis. 2017 Jan 1;215(1):52-55. doi: 10.1093/infdis/jiw501. Epub 2016 Oct 25.

22.

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM.

J Virol. 2017 Feb 14;91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1.

23.

Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D.

J Virol. 2017 Feb 14;91(5). pii: e02147-16. doi: 10.1128/JVI.02147-16. Print 2017 Mar 1.

24.

A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development.

Tsetsarkin KA, Kenney H, Chen R, Liu G, Manukyan H, Whitehead SS, Laassri M, Chumakov K, Pletnev AG.

MBio. 2016 Aug 23;7(4). pii: e01114-16. doi: 10.1128/mBio.01114-16.

25.

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.

Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP.

Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517. Epub 2016 Mar 16.

PMID:
27089205
26.

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2016 Sep 15;214(6):832-5. doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.

27.
28.

WITHDRAWN: Dengue Human Infection Models to Advance Dengue Vaccine Development.

Larsen CP, Whitehead SS, Durbin AP.

Vaccine. 2015 Oct 27. pii: S0264-410X(15)01424-3. doi: 10.1016/j.vaccine.2015.09.113. [Epub ahead of print]

PMID:
26501186
29.

Dengue human infection models to advance dengue vaccine development.

Larsen CP, Whitehead SS, Durbin AP.

Vaccine. 2015 Dec 10;33(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.

30.

Dengue viruses cluster antigenically but not as discrete serotypes.

Katzelnick LC, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, Russell CA, Thu HM, Pierson TC, Buchy P, Aaskov JG, Muñoz-Jordán JL, Vasilakis N, Gibbons RV, Tesh RB, Osterhaus AD, Fouchier RA, Durbin A, Simmons CP, Holmes EC, Harris E, Whitehead SS, Smith DJ.

Science. 2015 Sep 18;349(6254):1338-43. doi: 10.1126/science.aac5017.

31.

Soluble mediators produced by the crosstalk between microvascular endothelial cells and dengue-infected primary dermal fibroblasts inhibit dengue virus replication and increase leukocyte transmigration.

Bustos-Arriaga J, Mita-Mendoza NK, Lopez-Gonzalez M, García-Cordero J, Juárez-Delgado FJ, Gromowski GD, Méndez-Cruz RA, Fairhurst RM, Whitehead SS, Cedillo-Barrón L.

Immunol Res. 2016 Apr;64(2):392-403. doi: 10.1007/s12026-015-8675-8.

PMID:
26130295
32.

Dual miRNA targeting restricts host range and attenuates neurovirulence of flaviviruses.

Tsetsarkin KA, Liu G, Kenney H, Bustos-Arriaga J, Hanson CT, Whitehead SS, Pletnev AG.

PLoS Pathog. 2015 Apr 23;11(4):e1004852. doi: 10.1371/journal.ppat.1004852. eCollection 2015 Apr.

33.

Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice.

Gromowski GD, Firestone CY, Whitehead SS.

J Virol. 2015 Jun;89(12):6328-37. doi: 10.1128/JVI.00219-15. Epub 2015 Apr 8.

34.

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS.

J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22.

35.

Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.

Gromowski GD, Firestone CY, Bustos-Arriaga J, Whitehead SS.

Am J Trop Med Hyg. 2015 Jan;92(1):98-107. doi: 10.4269/ajtmh.14-0427. Epub 2014 Oct 13.

36.

Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey.

Hanley KA, Guerbois M, Kautz TF, Brown M, Whitehead SS, Weaver SC, Vasilakis N, Marx PA.

Am J Trop Med Hyg. 2014 Oct;91(4):672-6. doi: 10.4269/ajtmh.13-0492. Epub 2014 Aug 4.

37.

Mechanism and significance of cell type-dependent neutralization of flaviviruses.

Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC.

J Virol. 2014 Jul;88(13):7210-20. doi: 10.1128/JVI.03690-13. Epub 2014 Apr 16.

38.

Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4.

Gromowski GD, Firestone CY, Hanson CT, Whitehead SS.

Vaccine. 2014 May 23;32(25):3010-8. doi: 10.1016/j.vaccine.2014.03.062. Epub 2014 Mar 31.

39.

Corticosteroids for dengue - why don't they work?

Nguyen TH, Nguyen TH, Vu TT, Farrar J, Hoang TL, Dong TH, Ngoc Tran V, Phung KL, Wolbers M, Whitehead SS, Hibberd ML, Wills B, Simmons CP.

PLoS Negl Trop Dis. 2013 Dec 12;7(12):e2592. doi: 10.1371/journal.pntd.0002592. eCollection 2013.

40.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.

41.

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.

Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, Speicher J, Whitehead SS, Pletnev AG.

Vaccine. 2013 Nov 19;31(48):5772-7. doi: 10.1016/j.vaccine.2013.07.064. Epub 2013 Aug 19.

42.

Response to Ruiz-Alejo et al.

Durbin AP, Whitehead SS.

J Infect Dis. 2013 Oct 1;208(7):1184. doi: 10.1093/infdis/jit298. Epub 2013 Jul 11. No abstract available.

PMID:
23852125
43.

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD.

Vaccine. 2013 Jul 18;31(33):3347-52. doi: 10.1016/j.vaccine.2013.05.075. Epub 2013 Jun 2.

44.

Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE Jr.

J Infect Dis. 2013 Jun 15;207(12):1898-908. doi: 10.1093/infdis/jit119. Epub 2013 Mar 22.

45.

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS.

J Infect Dis. 2013 Mar 15;207(6):957-65. doi: 10.1093/infdis/jis936. Epub 2013 Jan 17.

46.

Replacement of conserved or variable sequences of the mosquito-borne dengue virus 3' UTR with homologous sequences from Modoc virus does not change infectivity for mosquitoes.

Tumban E, Maes NE, Schirtzinger EE, Young KI, Hanson CT, Whitehead SS, Hanley KA.

J Gen Virol. 2013 Apr;94(Pt 4):783-8. doi: 10.1099/vir.0.046664-0. Epub 2012 Dec 19.

47.

The dengue human challenge model: has the time come to accept this challenge?

Durbin AP, Whitehead SS.

J Infect Dis. 2013 Mar 1;207(5):697-9. doi: 10.1093/infdis/jis749. Epub 2012 Dec 5. No abstract available.

PMID:
23225898
48.

Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans.

Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, Kirkpatrick BD.

PLoS Negl Trop Dis. 2012;6(7):e1742. doi: 10.1371/journal.pntd.0001742. Epub 2012 Jul 17.

49.

Dengue research opportunities in the Americas.

Laughlin CA, Morens DM, Cassetti MC, Costero-Saint Denis A, San Martin JL, Whitehead SS, Fauci AS.

J Infect Dis. 2012 Oct 1;206(7):1121-7. doi: 10.1093/infdis/jis351. Epub 2012 Jul 9. Review.

50.

Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil.

Mahoney RT, Francis DP, Frazatti-Gallina NM, Precioso AR, Raw I, Watler P, Whitehead P, Whitehead SS.

Vaccine. 2012 Jul 6;30(32):4892-6. doi: 10.1016/j.vaccine.2012.02.064. Epub 2012 Mar 8.

PMID:
22406455

Supplemental Content

Loading ...
Support Center